'The market for Parkinson's disease drugs will reach $3754m in 2015' says visiongain report

The market for Parkinson's disease drugs generated $3351m in 2010, according to Parkinson's Disease: World Drug Market 2011-2021, published in September 2011. The Parkinson's treatment market has potential to expand. In 2011 there are more than 300 late-stage trials of Parkinson's drugs in progress.

Parkinson's disease is a prominent neurodegenerative disorder. Though it is primarily a movement disorder, with symptoms including tremor and bradykinesia, it often causes cognitive effects including dementia and psychosis. Because Parkinson's affects mostly the elderly, the ageing of the world population will result in its prevalence increasing, giving opportunities to the pharmaceutical industry.

The disease remains chronic and incurable, but since the 1960s treatments have relieved some of the symptoms. Many treatments are approaching - or have reached - commercial maturity, but a strong R&D pipeline stands ready to replace them. Visiongain's report discusses leading drug candidates, including new adenosine receptor antagonists. That study covers Boehringer Ingelheim, Novartis, GSK, Teva and many other companies, predicting revenues and developmental trends to 2021.

Visiongain's healthcare industry analyst, says: "Parkinson's remains the most treatable of the neurodegenerative diseases, but the industry needs a new approach to supplement dopaminergic therapies. Longer term, gene therapies, biomarkers and stem cells point the way to disease modification and an eventual cure. In coming years, adenosine receptor antagonists will boost the Parkinson's treatment armoury. Those drugs offer a way to bypass the dopamine system and restore damaged communicational links in the brain. Kyowa Hakko Kirin has the leading product candidate."

Research and analyses from visiongain's report indicate that scientific and industrial studies of Parkinson's disease will yield important developments in the next ten years. While dopaminergic treatments will remain important, drugs with other mechanisms of action will enter the market and improve treatment of patients.

Visiongain predicts that the Parkinson's treatment market will grow steadily to 2021, with some existing drugs being superseded by newer treatments. This new report adds to visiongain's wide range of analytical reports for healthcare and other industries.

To see sample pages of the report please visit http://www.visiongain.com/Report/689/Parkinson%27s-Disease-World-Drug-Market-2011-2021

To request an exec summary please contact Sara Peerun on:
Email: sara.peerun@visiongainglobal.com
Tel: +44 0 20 7336 6100

ENDS

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

Visiongain Ltd
230 City Road
London
EC1V 2QY
United Kingdom

This release was published on openPR.